16. Tolerance of radiotherapy (3D-CRT) and androgen ablation for patients with prostate cancer

Abstract

Purpose

Evaluation acute tolerance of combined treatment (XRT and HT).

Material/methods

Between April 1999 and September 2000, 22 patients with prostate cancer (T1-T3NXMO) were treated with 3D-CRT and HT. Median age of patients was 68 years. EBRT was administered daily fraction of 1.8 Gy,total dose 70.2 Gy. Planning target volume (PTV) was defined as clinical target volume CTV (prostate and seminal vesicles) with 10 mm margins around prostate except posterior margin where 5 mm were used to decrease risk of rectum morbidity. Acute toxicities were evaluated using RTOG scoring scale. Median follow-up was 11 months.

Results

Acute effects in gastrointestinal tract (GI) noted were; rectal discomfort and mild diarrhea. Acute genitourinary (GU) symptoms included urgency, nocturia and dysuria. GI toxicity was observed in 75% of patients (grade 0 and 1), and 25% of patients (grade 2). GU toxicities were as follow: grade 0 and 1 – 80% of patients) and grade 2 – (20% of patients). No grade 3 or 4 GI and GU toxicities were observed.

Conclusions

Preliminary results of treatment with 3D-CRT suggested that such modality is well tolerated. HT did not exacerbate radiation toxicity.